Thanks to @netta_doc for being instrumental in building #ASKWAF into one of our attendees’ favorite sessions! 🙏 Can’t wait to bring it back at #WAFIB2027. Bring your toughest AF questions — our faculty will be ready! #ASKWAF #AFib #EPeeps @PrashSanders @NazemAkoum @AndreaRussoEP @Dr_Santangeli @S_NarayanMD @TinaBaykaner @drluissaenz @drsuneet @JonPicciniSr @DrDave01 @CMAlbertEP @TulaneTriad

Very important message from our group. In patients with recurrent AF after a first ablation, what we do next matters. Repeat catheter ablation was associated with a 35% lower risk of death, stroke, or HF hospitalization compared with cardioversion, with an NNT of only 14. This challenges the idea that management of recurrent AF should simply be based on operator preference. Recurrence after ablation should not be viewed as failure—it may be an opportunity to intervene again and improve meaningful clinical outcomes. Congratulations to @mabou_khalil @HanFengGHD @QMarashly and the entire team. #AFib #Ablation #EPeeps @PrashSanders @shivkumarmd @gautamsand @S_NarayanMD @Phiso_de @drsuneet @drjohnm @drluissaenz @leftbundle @KennethEllenbo1 @DrBradleyKnight @DrRoderickTung @atulverma_md

AF recurs in up to 50% post-ablation, what's next is often just operator preference. Our study in Europace of 3,100+ patients: redo ablation cut death/stroke/HF by 35% vs. cardioversion (NNT=14). 🫀⚡ @nmarrouche @HanFengGHD @QMarashly 📄 doi.org/10.1093/europace/eua… #AFib #EPeeps

When conventional approaches are limited, there are always options. A completely leadless CRT-D strategy ⚡️ Micra AV + Aurora EV-ICD + WiSE-CRT @EBRSystemsInc @MDT_Cardiac @TulaneTriad @TulaneMedicine @SheaQarqish @nmarrouche

Congratulations @QMarashly and our clinical team on this remarkable achievement! A completely leadless CRT-D strategy is a truly novel step beyond conventional approaches. Awesome work!👏

Easy access, long-term follow-up, and continuous insights beyond the clinic make PPG uniquely powerful. With #AI, we at #TRIAD #TulaneHVI are expanding what we can measure outside the clinic and exploring a new model of bringing cardiovascular care into patients’ daily lives.

The #PPG (wearable photoplethysmography sensors) in medicine summerized 👇🏼@EricTopol @iamthezack @drjohnm @DrDave01 @TulaneTriad @tulaneHeart @TulaneMedicine @HanFengGHD @YingshuoL

Excited to share that the HEARTBEAT study design is out! Let’s see where PPG assessment in a real-world setting can lead us to in Cardiovascular medicine! @nmarrouche @MassadChristian @HanFengGHD @chanholim @AlaAssaf3 @BsoulMayana @TulaneTriad @QMarashly academic.oup.com/ehjdh/advan…

A major step toward understanding what continuous, real-world wearable monitoring can tell us beyond the clinic. Proud of the team behind #HEARTBEAT — and even more excited for the clinical outcome findings coming next. Stay tuned! #DigitalHealth #CardvascularDisease #Wearables

Great work by @HanFengGHD and @MekhaelMario. Another important lesson from DECAAF II: the atrium matters. LA remodeling and volume are not simply markers of AF—they help define the substrate, predict outcomes after ablation, and should inform how we select, counsel, and follow our patients. #DECAAFII #AFib #EP @drjohnm @AkihikoNogami @NazemAkoum @MDTolgaAksu @PrashSanders @S_NarayanMD @Nishaki1 @TulaneTriad

PVI alone was successful in 72.5% of patients with persistent AF and a LA volume of <114 cc at 1year follow up. Check out our piece in @JACCJournals @HanFengGHD @nmarrouche @OmarKreidieh1 @chowbacca64 @AmitabhCPandey @drjohnm @TulaneTriad doi.org/10.1016/j.jacadv.202…

A major development in the 2026 ESC Heart Failure Guidelines is the move toward a simpler EF cutoff: HF with LVEF <50% versus HF with LVEF ≥50% — moving away from the traditional three-way separation of HFrEF, HFmrEF, and HFpEF. And within this new framework, the guidelines send another clear message: AF in heart failure is no longer just a rate-control problem. ➡️ When #AFib is driving LV dysfunction, restoring sinus rhythm is recommended, with catheter ablation playing a central role. ➡️ In selected patients with #AFib and HFrEF, catheter ablation should be considered to reduce heart failure hospitalization and improve survival. ➡️ In HFpEF, the evidence gap remains, and treatment decisions should be individualized. The guidelines also highlight an old friend: digoxin. Once pushed to the sidelines, it again has a role in rate control for patients with AF and heart failure, particularly when other agents are ineffective, contraindicated, or poorly tolerated. The key message for patients is simple: AF may be a driver of heart failure, not merely a consequence. Recognizing and treating it early could improve symptoms and outcomes. The next frontier is clear: can eliminating AF change the natural history of HFpEF? #CASTLEHFpEF #ESC2026 #ESCCongress #AtrialFibrillation #HeartFailure #HFrEF #HFpEF #Ablation @lamcardio @Phiso_de @chris_sohns @shivkumarmd @S_NarayanMD @drjohnm @TulaneTriad @TulaneHeart

Important data from #PIPPAF_PFA at #ESCCongress, but in my view the primary endpoint—recurrence of any atrial tachyarrhythmia—is a relatively weak measure of treatment effect in persistent #AFib. AF burden may be the more clinically and biologically meaningful endpoint, and notably, the burden data in this study appeared more favorable with PWI (6.9% vs 11%) The larger message, however, is not whether we should empirically add posterior wall isolation to every PVI. We should be moving away from empirical “one-size-fits-all” ablation beyond the pulmonary veins. #AFib is a heterogeneous disease. As we have learned from studies including DECAAF II and #CAPLA, simply adding ablation based on anatomy alone does not necessarily improve outcomes. The challenge is to identify which patient, which atrial substrate, and which target will benefit from additional ablation. The future should be integration of atrial structure and #fibrosis, the spatial and temporal behavior of AF, and increasingly AI-derived phenotyping to individualize what we do beyond PVI—not simply adding another empirical lesion set. Beyond PVI, the question should no longer be “what else should we ablate?” but “who needs additional ablation, where, and why?” #AtrialFibrillation #PFA #AFib #CardiacEP #AI @S_NarayanMD @drjohnm @peterkistler3 @Phiso_de @AndreaSarkozy @TinaBaykaner @DrRoderickTung @purerfellner @TulaneTriad @TulaneHeart

The power of #PPG in changing medicine being unlocked @ @TulaneTriad @TulaneMedicine!

Great presentation by our MS2, Soubhi Tahhan, highlighting better long-term outcomes in dialysis dependent patients receiving SAVR compared to TAVR. Check out our pre-proof simultaneous publications in @AATSJournals : jtcvs.org/article/S0022-5223… @jamil_borgi @JAJishu1 @HanFengGHD

Honored and grateful for the opportunity to share my experience at #AATS26 through my platforms! Follow me for a special focus on mitral valve, heart transplantation and perioperative AF🫀@AATSHQ @AATSJournals @jamil_borgi @nmarrouche @HanFengGHD @Tulane_Surgery @TulaneTriad

A star @YaraMenassa! #Proud @TulaneTriad

Day 1 at #AATS26! So excited for all the surgical science and discussions. Let’s go! @AATSHQ @AATSJournals @jamil_borgi @Tulane_Surgery @TulaneTriad @HanFengGHD